← ANALYST RATINGS · TIPRANKS
Sight Sciences (SGHT): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months · top analysts only12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $8.50, the highest $9.00, the lowest $8.00. The average is +2.7% from the last price of $8.28.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Yi Chen★★★★★★★★★★#10518 · hits 41% · avg −1.0% | H.C. Wainwright | $14.00 | Buy | +69.1% | Initiated | 15.10.26on TipRanks 06:20 | +6.4%next day −4.8% | ↗ |
| Joanne Wuensch★★★★★★★★★★#3684 · hits 55% · avg +2.3% | Citi | $8.00 → $10.00+25.0% | Hold | +20.8% | Assigned | 05.10.26on TipRanks 07:16 | +3.9%next day −4.6% · 5 days +0.1% | ↗ |
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $9.00 → $10.00+11.1% | Hold | +20.8% | Reiterated | 29.09.26on TipRanks 06:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $8.50 → $10.00+17.6% | Hold | +20.8% | Reiterated | 29.09.26on TipRanks 06:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $8.50 → $9.50+11.8% | Hold | +14.7% | Reiterated | 29.09.26on TipRanks 06:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $8.50 → $9.50+11.8% | Hold | +14.7% | Reiterated | 29.09.26on TipRanks 06:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $8.50 → $10.00+17.6% | Hold | +20.8% | Reiterated | 29.09.26on TipRanks 06:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $8.50 → $9.50+11.8% | Hold | +14.7% | Reiterated | 29.09.26on TipRanks 06:05 | — | |
| Frank Takkinen★★★★★★★★★★#11823 · hits 38% · avg −3.6% | Lake Street | $12.00 | Buy | +44.9% | Reiterated | 19.08.26on TipRanks 09:13 | +2.8%next day −2.9% · 5 days −0.8% | ↗ |
| Steven Lichtman★★★★★★★★★★#568 · hits 54% · avg +14.7% | William Blair | — | Buy | — | Reiterated | 06.08.26on TipRanks 14:45 | +27.9%next day +4.7% · 5 days +16.1% | ↗ |
| Thomas Stephan★★★★★★★★★★#3049 · hits 47% · avg +8.4% | Stifel Nicolaus | $8.00 | Buy | −3.4% | Reiterated | 06.08.26on TipRanks 12:45 | +27.9%next day +4.7% · 5 days +16.1% | ↗ |
| Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% | UBS | $7.00 → $8.00+14.3% | Buy | −3.4% | Reiterated | 06.08.26on TipRanks 08:01 | +27.9%next day +4.7% · 5 days +16.1% | ↗ |
| David Saxon★★★★★★★★★★#6662 · hits 38% · avg +0.8% | Needham | — | Hold | — | Reiterated | 06.08.26on TipRanks 07:15 | +27.9%next day +4.7% · 5 days +16.1% | ↗ |
| Adam Maeder★★★★★★★★★★#1026 · hits 54% · avg +11.3% | Piper Sandler | $9.00 | Buy | +8.7% | Reiterated | 06.08.26on TipRanks 07:01 | +27.9%next day +4.7% · 5 days +16.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Sight Sciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $9.00 at a price of $9.36 (−3.8%); now: $10.17 at $8.28 (+22.8%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 2 | 2 | 0 | 0 | 0 |
| Buy | 3 | 1 | 1 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.13 (from $-0.16 to $-0.09). Last quarter: $-0.08.
Sales
Next quarter’s sales estimate — $24M (from $23M to $24M). Last quarter: $23M.
Best top-analyst consensus in the sector · Healthcare
About Sight Sciences
- CEO: Paul Badawi
- Employees: 186
- 4040 Campbell Avenue, Menlo Park, CA, 94025, US
- www.sightsciences.com
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.
Data from the stock’s TipRanks forecast page, read 114 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗